Ocuphire Pharma

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

The stock price of Ocuphire Pharma Inc (NASDAQ: OCUP) increased by over 30% during intraday trading this morning. This is why it happened.

OCUP Stock Price Increases Over 30%: Why It Happened

Ocuphire Pharma Inc (NASDAQ: OCUP) announced data from the VEGA-1 Phase 2 trial evaluating the efficacy and safety of Nyxol in combination with low-dose pilocarpine (LDP) in presbyopic subjects.  Presbyopic is the gradual loss of the eye's ability to focus on nearby objects.

Ocuphire Pharma Stock Surges After Nyxol Combo Treatment Meets Study Endpoints In Presbyopic Patients

Met primary endpoint with statistical significance at 1 hour with 61% of subjects treated with Nyxol ® plus low-dose pilocarpine (LDP) gaining ≥ 15 letters (3 lines) in near vision

Ocuphire's VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints

Processa Pharmaceuticals

Processa Pharmaceuticals Inc (NASDAQ: PCSA) has entered into a licensing agreement with Ocuphire Pharma Inc (NASDAQ: OCUP) to in-license RX-3117. RX-3117 is an oral anticancer agent with an improved pharmacological profile relative to gemcitabine and other nucleoside analogs.

Processa Pharmaceuticals In-Licenses Ocuphire's Anticancer Agent

FARMINGTON HILLS, Mich., June 11, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on development and commercialization of therapies for the treatment of several eye disorders, today announced that the Company is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted June 4, 2021.

Ocuphire Announces Addition to the Russell Microcap® Index

Capital Raise Expected to Extend Runway Through Late 2022 and Allow Additional Milestones for a Potential NDA Filing for Nyxol in Reversal of Mydriasis Capital Raise Expected to Extend Runway Through Late 2022 and Allow Additional Milestones for a Potential NDA Filing for Nyxol in Reversal of Mydriasis

Ocuphire Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market

FARMINGTON HILLS, Mich., June 04, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 3,076,923 shares of the Company's common stock (the “Shares”) and warrants to purchase 1,538,461 shares of the Company's common stock (the “Warrants”, and together with the Shares, the “Securities”) at a combined purchase price of $4.875 per one Share and 0.5 Warrant in a registered direct offering priced at-the-market under Nasdaq rules. The Warrants will have an exercise price of $6.09 per share, will be exercisable on issuance date, and will expire five years following the issuance date. The closing of the offering is expected to occur on or about June 8, 2021, subject to the satisfaction of customary closing conditions.

Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Highlights of Recent Positive Data from Nyxol's Phase 3 Registration Trial

Ocuphire to Host Key Opinion Leader Event on Nyxol® as a Potential New Treatment Option for Reversing Pharmacologically Induced Mydriasis

Newly Issued Claims Extend Patent Protection to Year 2039 for Nyxol ® Combination Therapy for Presbyopia

Ocuphire Granted Two New U.S. Patents Covering Late-Stage Drug Candidate Nyxol®, Including for the Treatment of Presbyopia

Ocuphire recently became publicly traded in November 2020 after a reverse merger with Rexahn Pharmaceuticals. Ocuphire has a suite of ophthalmology products targeting both front and back of the eye indications, including one that just readout positive Phase 3 results.

Ocuphire's Low Market Cap Masks Significant Pipeline Potential

Reported Positive Data in First Pivotal Phase 3 Trial for Nyxol Eye Drops with Plans to Advance Towards NDA Submission and Commercialization in Reversal of Mydriasis Indication

Ocuphire Announces Financial Results for the First Quarter 2021 and Provides Corporate Update

Oral Administration of APX3330 Reduced Neovascularization in a Pre-Clinical Mouse Model of Laser-Induced Choroidal Neovascularization

Ocuphire's APX3330 for Retinal Diseases to be Presented at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting

Ocuphire Pharma Inc (NASDAQ: OCUP) has screened the first patient in Phase 2 ZETA-1 trial evaluating APX3330 in non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (mild PDR). Effects on diabetic macular edema will be explored as a secondary outcome.

Ocuphire Pharma Starts Mid-Stage APX3330 Study In Diabetic Retinopathy Patients

APX3330 has the Potential to be a Novel Oral Treatment Option with Dual Mechanism of  Anti-VEGF and Anti-Inflammatory for Diabetic Retinopathy

Ocuphire Initiates ZETA-1 Phase 2 Clinical Trial Investigating APX3330 in Diabetic Retinopathy

The shares of Ocuphire Pharma Inc (NASDAQ: OCUP) have increased by over 10% pre-market. This is why it happened.

Ocuphire Pharma Stock Price: $25 Target By Alliance Global Partners

The stock price of Ocuphire Pharma, Inc. (Nasdaq: OCUP) is trading at over 90% pre-market as of 6:47 AM ET today. This is why it happened.

OCUP Stock Price Increases Over 90% Pre-Market: Why It Happened

Ocuphire Pharma Inc (NASDAQ: OCUP) stock is soaring in the premarket in reaction to positive data from MIRA-2 Phase 3 trial evaluating Nyxol. Nyxol is an eye drop formulation of phentolamine mesylate designed to reverse pharmacologically induced mydriasis (dilation of pupil for eye exams).

Ocuphire Pharma Stock Is Trading Higher After Nyxol Aces Late-Stage Study

Nyxol Meets Its Primary and Multiple Secondary Endpoints Including Statistically Significant Efficacy Returning Subjects More Rapidly to Normal Pupil Size Across a Breadth of Dilating Agents and Iris Colors

Ocuphire Announces MIRA-2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary Endpoint

FARMINGTON HILLS, Mich., March 10, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced financial results for the full year 2020 and provided a corporate update.

Ocuphire Announces Financial Results for the Full Year 2020 and Provides Corporate Update

Efficacy Across Mydriatic Agents in Reversing Pharmacologically Induced Mydriasis Informed Phase 3 Registration MIRA-2 Study Design

Ocuphire Announces Publication of MIRA-1 Phase 2b Results in Optometry and Visual Science Demonstrating Reduction of Pharmacologically Induced Mydriasis by Nyxol®

HC Wainwright Life Sciences Conference beginning at 7:00 am ET on March 9th Oppenheimer Healthcare Conference at 9:20 am ET on March 18th

Ocuphire to Participate in March Investor Conferences

Nyxol and Low-Dose (0.4%) Pilocarpine Combination to Target Improvement in Near Vision in a Presbyopic Population

Ocuphire Initiates Enrollment in VEGA-1 Phase 2 Trial Investigating Nyxol in Presbyopia

FARMINGTON HILLS, Mich., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced today that Mina Sooch, Chief Executive Officer will present a corporate overview at the 2021 BIO CEO & Investor Conference and participate in select one-on-one investor meetings from February 16 to 18, 2021. Ocuphire's management will also participate in Cantor Fitzgerald's Eyeing Key Events and Programs in the Ophthalmology Space in 2021 Panel on February 19, 2021 at 10:30am EST.

Ocuphire to Participate in the 2021 BIO CEO & Investor Conference and Cantor Fitzgerald's Panel on Eyeing Key Events in the Ophthalmology Space in 2021

Durability of Nyxol's Pupil Constricting Effects Using an Evening Dosing Regimen Informs Dosing Strategy for Phase 2 Trial in Presbyopia and Phase 3 Trial in NVD

Ocuphire Announces Publication of ORION-1 Phase 2 Results for Nyxol in Clinical Ophthalmology and Presentation at the January OIS Presbyopia Innovation Showcase

FARMINGTON HILLS, Mich., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced today that Mina Sooch, President and Chief Executive Officer, will make a corporate presentation at the LifeSci Partners 10th Annual Healthcare Corporate Access Event, on Thursday, January 7, 2021 at 11am Eastern Time.

News for Ocuphire Pharma Stock (OCUP)